First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5): a feasibility study and comparative analysis of the SCOTROC series

Scottish Gynecological Cancers Trials Group, Roshan Agarwal, Charles Gourley, Timothy J Perren, Nicholas Reed, David E Parkin, Karen Carty, Gordon J S Rustin, Hani Gabra, Jim Paul, Martin E Gore, Stanley B Kaye

Research output: Contribution to journalArticlepeer-review

Abstract

We have conducted a series of four feasibility studies in stage Ic-IV ovarian cancer exploring six sequential first-line schedules with the same entry criteria in a total of 339 patients. Here we present the results of the sixth study, and an analysis of the overall series.
Original languageEnglish
Pages (from-to)2020-6
Number of pages7
JournalEuropean Journal of Cancer
Volume46
Issue number11
DOIs
Publication statusPublished - 2010

Keywords

  • Carboplatin
  • Paclitaxel
  • Gemcitabine
  • Sequential therapy
  • Ovarian cancer

Fingerprint Dive into the research topics of 'First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5): a feasibility study and comparative analysis of the SCOTROC series'. Together they form a unique fingerprint.

Cite this